Anthony D. Pomicter

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Daniel Bottomly, Nicola Long, Anna Reister Schultz et al. · Cancer Cell · 2022 · 368 citations · Full text

Medicine, Cancer Biology, Oncology +17

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 366 citations · Full text

Medicine, Molecular Biology, Oncology +7

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage et al. · Cancer Cell · 2019 · 245 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 223 citations

Medicine, Molecular Biology, Oncology +14

Age-related mutations and chronic myelomonocytic leukemia

Clinton C. Mason, Jamshid S. Khorashad, Srinivas K. Tantravahi et al. · Leukemia · 2015 · 141 citations · Full text

Life Sciences, Genetics, Hematology +14